{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-144970","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.548977+00:00","generated_at":"2026-06-25T22:26:12.272090+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Revolution Medicines Q1 net loss $57.6M; RAS(ON) inhibitors advancing toward clinic","bullets":["Net loss $57.6M vs $37.2M YoY; revenue $7.6M from Sanofi collaboration (down from $10.2M).","Cash and securities $518.8M at Mar 31, 2022, down from $577.1M at Dec 31, 2021.","FY 2022 net loss guidance reaffirmed at $260M-290M, including $35M-40M stock-based comp.","IND submitted for RMC-6236 (RAS MULTI); first patient dosing mid-2022. RMC-6291 IND on track for H1 2022.","RMC-4630 Phase 2 combo with sotorasib enrolling; enrollment completion expected H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-144970","json":"https://secwatch.observer/filing/0001193125-22-144970.json","markdown":"https://secwatch.observer/filing/0001193125-22-144970.md","text":"https://secwatch.observer/filing/0001193125-22-144970.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522144970/0001193125-22-144970-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312522144970/d285264d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:26:12.272090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}